TrialBritish journal of clinical pharmacology2015

Antisense-mediated reduction of proprotein convertase subtilisin/kexin type 9 (PCSK9): a first-in-human randomized, placebo-controlled trial.

Eveline P van Poelgeest et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.